Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio [Seeking Alpha]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Seeking Alpha
CEO David Moatazedi described Evolus' focus on a "performance beauty strategy" centered around a cash-pay aesthetic model, emphasizing differentiation through partnerships and loyalty programs. Moatazedi highlighted the launch of Evolux, a program that rewards clinics with co-branded Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market. Subscribe to Stock Ideas Sign Up Quick Insights Evolus expects 2026 revenues of $327M-$337M (10%-13% growth) and full-year profitability with a low to mid single-digit adjusted EBITDA margin. Evolus is broadening adoption of Evolysse, launching Estyme in Europe, expanding loyalty and rebate programs, and targeting FDA approval of Evolysse Sculpt to strengthen its brand and market share. Key risks include tariff exposure on French imports, two major competitor toxin launches, persistent filler market weakness, and clinic inventories that have not fully recovered. More T
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- AEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Evolus, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Evolus (EOLS) had its "buy" rating reaffirmed by BTIG Research. They now have a $13.00 price target on the stock.MarketBeat
- Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 3/3/26 - Beat
EOLS
Sec Filings
- 3/3/26 - Form S-8
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- EOLS's page on the SEC website